Mod GRF 1-29 (CJC-1295 No Dac)

Overview of MOD‑GRF‑1‑29 

MOD-GRF-1-29, also called CJC‑1295 without DAC or Modified Growth Hormone‑Releasing Factor (1‑29). 

It is a synthetic peptide analog of the growth hormone‑releasing hormone (GHRH). It represents the first 29 amino acids of GNRH, with specific amino acid substitutions.

Researchers believe that, unlike full GHRH, MOD‑GRF‑1‑29’s modifications increase its half‑life to about ~30 minutes.

Working Mechanism of MOD-GRF-1-29

Researchers have observed that MOD‑GRF‑1‑29 may bind to GHRH receptors on anterior pituitary cells in preclinical research models. This triggers intracellular signaling that may elevate cyclic AMP (cAMP) and increase GH synthesis. 

Research indicates that mod-grf-1-29 may stimulate discrete GH pulses that more closely mimic natural hormone rhythms. 

Research Applications of Mod-Grf-1-29

Mod-Grf-1-29 is studied in controlled laboratory models for the following potential research applications.

• Somatotropic signaling dynamics
• Endocrine axis modulation and temporal signaling shifts
• Metabolic flux and compositional variability analysis
• Regenerative signaling cascades and repair-associated processes

Why Buy Mod-Grf-1-29 Online from Purerawz?

You can buy mod-grf-1-29 from our online shop at reasonable prices. Each batch of this product undergoes rigorous testing for purity, identity, and contaminants, ensuring consistency and safety. 

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By placing an order, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use

Reference Links

• Ranke, M. B., Gruhler, M., R. Rosskamp, G. Brügmann, Attanasio, A., Blum, W. F., & Bierich, J. R. (1986). Testing with growth hormone-releasing factor (GRF(1–29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency. European Journal of Pediatrics, 145(6), 485–492. https://doi.org/10.1007/bf02429048
• Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., Pieter van Wyk, Pham, K., & Bridon, D. (2005). Human Growth Hormone-Releasing Factor (hGRF)1–29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology, 146(7), 3052–3058. https://doi.org/10.1210/en.2004-1286
• Valcavi, R., Jordan, V., Dieguez, C., John, R., Manicardi, E., Portioli, I., Rodriguez-Arnao, M. D., Gomez-Pan, A., Hall, R., & Scanlon, M. F. (1986). Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clinical Endocrinology, 24(6), 693–698. https://doi.org/10.1111/j.1365-2265.1986.tb01666.x